Market Cap (In USD)
12.16 Million
Revenue (In USD)
-
Net Income (In USD)
-14.57 Million
Avg. Volume
63.34 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.72-5.28
- PE
- -
- EPS
- -
- Beta Value
- -1.722
- ISIN
- US00510M1045
- CUSIP
- 00510M104
- CIK
- 1736243
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. David P. Luci CPA, Esq., J.D.
- Employee Count
- -
- Website
- https://www.acurxpharma.com
- Ipo Date
- 2021-06-25
- Details
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
More Stocks
-
8542Tomato Bank, Ltd.
8542
-
VUL
-
E8Xelexxion AG
E8X
-
CFL
-
8801
-
BBN
-
000660SK hynix Inc.
000660
-
002611